Anti-FGFR2/ BBDS/ BEK monoclonal antibody

Anti-FGFR2/ BBDS/ BEK antibody for FACS & in-vivo assay

Target products collectionGo to FGFR2/FGFR2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T58454-Ab-1/ GM-Tg-hg-T58454-Ab-2Anti-Human FGFR2 monoclonal antibodyHuman
GM-Tg-rg-T58454-Ab-1/ GM-Tg-rg-T58454-Ab-2Anti-Rat FGFR2 monoclonal antibodyRat
GM-Tg-mg-T58454-Ab-1/ GM-Tg-mg-T58454-Ab-2Anti-Mouse FGFR2 monoclonal antibodyMouse
GM-Tg-cynog-T58454-Ab-1/ GM-Tg-cynog-T58454-Ab-2Anti-Cynomolgus/ Rhesus macaque FGFR2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T58454-Ab-1/ GM-Tg-felg-T58454-Ab-2Anti-Feline FGFR2 monoclonal antibodyFeline
GM-Tg-cang-T58454-Ab-1/ GM-Tg-cang-T58454-Ab-2Anti-Canine FGFR2 monoclonal antibodyCanine
GM-Tg-bovg-T58454-Ab-1/ GM-Tg-bovg-T58454-Ab-2Anti-Bovine FGFR2 monoclonal antibodyBovine
GM-Tg-equg-T58454-Ab-1/ GM-Tg-equg-T58454-Ab-2Anti-Equine FGFR2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T58454-Ab-1/ GM-Tg-hg-T58454-Ab-2; GM-Tg-rg-T58454-Ab-1/ GM-Tg-rg-T58454-Ab-2;
GM-Tg-mg-T58454-Ab-1/ GM-Tg-mg-T58454-Ab-2; GM-Tg-cynog-T58454-Ab-1/ GM-Tg-cynog-T58454-Ab-2;
GM-Tg-felg-T58454-Ab-1/ GM-Tg-felg-T58454-Ab-2; GM-Tg-cang-T58454-Ab-1/ GM-Tg-cang-T58454-Ab-2;
GM-Tg-bovg-T58454-Ab-1/ GM-Tg-bovg-T58454-Ab-2; GM-Tg-equg-T58454-Ab-1/ GM-Tg-equg-T58454-Ab-2
Products NameAnti-FGFR2 monoclonal antibody
Formatmab
Target NameFGFR2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FGFR2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-057Pre-Made Bemarituzumab biosimilar, Whole mAb, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody
    BiosimilarGMP-Bios-INN-737Pre-Made Aprutumab Ixadotin Biosimilar, Whole Mab Adc, Anti-Fgfr2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-031Pre-Made Aprutumab biosimilar, Whole mAb ADC, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species FGFR2/ BBDS/ BEK VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T58454-Ag-1fibroblast growth factor receptor 2 (FGFR2) protein
    ORF Viral VectorpGMLV000611human FGFR2 Lentivirus plasmid
    ORF Viral VectorvGMLV000611human FGFR2 Lentivirus particle
    ORF Viral VectorpGMLPm003557mouse Fgfr2 Lentivirus plasmid
    ORF Viral VectorvGMLPm003557mouse Fgfr2 Lentivirus particle


    Target information

    Target IDGM-T58454
    Target NameFGFR2
    Gene ID2263,14183,25022,715949,415125,101095198,404193,100033956
    Gene Symbol and SynonymsBBDS,BEK,BFR-1,CD332,CEK3,CFD1,ECT1,FGFR,Fgfr-2,Fgfr-7,FGFR2,Fgfr2b,fgfr2IIIb,FGFR2IIIC,Fgfr7,JWS,K-SAM,KGFR,KGFRTr,svs,TK14,TK25
    Uniprot AccessionP21802
    Uniprot Entry NameFGFR2_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, INN Index, Cytokine Target
    DiseaseNon-Small Cell Lung Cancer
    Gene EnsemblENSG00000066468
    Target ClassificationKinase

    The target: FGFR2, gene name: FGFR2, also named as BBDS, BEK, BFR-1, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25. The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.